The Infectious Disease Research Institute, a Seattle-based nonprofit research center, said today it it is offering a critical ingredient to manufacturers that could increase the world supplies of flu vaccine. IDRI has developed adjuvants, or immune-boosting compounds, that make it possible to give smaller doses that can still protect people against infection. The announcement came shortly after the World Health Organization officially declared a global swine flu pandemic.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
